Related Experiment Video

Updated: Jul 30, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual

Kazuhito Suzuki1, Shingo Yano1

  • 1Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-Shimbashi, Minato-ku, Tokyo 105-0003, Japan.

Cancers
|May 13, 2023
PubMed

Insights

Current multiple myeloma treatments fail ultra-high-risk patients. Addressing minimal residual disease (MRD) and the bone marrow microenvironment is crucial for improving outcomes in these challenging cases.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma remains incurable despite advances in therapeutics like proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and autologous stem cell transplantation (ASCT).
  • Standard and high-risk cytogenetic patients often achieve minimal residual disease (MRD) negativity with four-drug induction therapy followed by ASCT, preventing disease progression.
  • However, this regimen is insufficient for patients with ultra-high-risk chromosomal aberrations (UHRCA), who experience poor outcomes, especially with MRD positivity post-therapy.

Purpose of the Study:

  • To review strategies for improving clinical outcomes in multiple myeloma patients with UHRCA.
  • To emphasize the importance of considering MRD assessment results in treatment planning.
  • To explore methods for enhancing the bone marrow microenvironment to combat aggressive myeloma.

Main Methods:

  • This review synthesizes current research on multiple myeloma treatment efficacy.
  • It analyzes the impact of minimal residual disease (MRD) status on outcomes after ASCT.
  • It discusses the role of the bone marrow microenvironment in disease progression and therapeutic response.

Main Results:

  • Minimal residual disease (MRD) status in autografts is a significant predictor of clinical outcomes post-ASCT.
  • Ultra-high-risk chromosomal aberrations (UHRCA) present a major challenge, with current therapies inadequately overcoming their negative prognostic impact.
  • High-risk myeloma cells not only exhibit aggressive behavior but also create a detrimental bone marrow microenvironment.

Conclusions:

  • Current treatment strategies are insufficient for multiple myeloma patients with UHRCA and MRD positivity.
  • Early intervention, focusing on MRD assessment and microenvironment modulation, is critical for improving outcomes.
  • Future therapeutic approaches must address the unique challenges posed by UHRCA to achieve a cure.
Keywords:
minimal residual diseasemultiple myelomatreatmentultra-high-risk chromosomal abnormalities

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.4K
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
365